Table 2 Baseline patient characteristics, N = 12,949

Patient type

< 0.001

 Existing T2DM patients

9,647 (74.5)

6,925 (75.7)

2,722 (71.5)

 New T2DM patients or new to practice

3,302 (25.5)

2,217 (24.3)

1,085 (28.5)

Age (mean, SD)

67.35 ± 12.47

range [19–105]

67.38 ± 12.40

range [20–101]

67.27 ± 12.65

range [19–105]

0.649

Gender

0.028

 Female

6,960 (53.7)

4,857 (53.1)

2,103 (55.2)

 Male

5,989 (46.3)

4,285 (46.9)

1,704 (44.8)

Race

< 0.001

 White

8,417 (65.0)

6,286 (68.8)

2,131 (56.0)

 Black or African American

3,565 (27.5)

2,268 (24.8)

1,297 (34.1)

 Asian

346 (2.7)

211 (2.3)

135 (3.5)

 American Indian, Alaska Native, Native Hawaiian, or Pacific Islander

63 (0.5)

39 (0.4)

24 (0.6)

Other or unknown

558 (4.3)

338 (3.7)

220 (5.8)

Ethnicity, Latino Hispanic

< 0.001

 Latino or Hispanic

429 (3.3)

264 (2.9)

165 (4.3)

 Non-Latino/Hispanic or Unknown

12,520 (96.7)

8,878 (97.1)

3,642 (95.7)

 Body Mass Index (BMI)

33.55 ± 7.43

33.61 ± 7.44

33.42 ± 7.41

0.196

Smoking status

.078

 Smoker

1,697 (13.1)

1,238 (13.5)

459 (12.1)

Mean baseline A1c*

6.86 ± 0.87

6.86 ± 0.87

6.87 ± 0.86

0.492

Receipt of lancet or test strip Rx, baseline*

3,835 (29.6)

2,789 (30.5)

1,046 (27.5)

0.001

Medication

 Sulfonylurea or glinide

2,591 (20.0)

1,824 (20.0)

767 (20.1)

.800

 GLP-1 analog, SGLT 2 inhibitor, or DPP-IV

3,061 (23.6)

2,123 (23.2)

938 (24.6)

.084

 Some other oral medication

7,200 (55.6)

4,984 (54.5)

2,216 (58.2)

<.001

 No oral medication

4,932 (38.1)

3,602 (39.4)

1,330 (34.9)

<.001

Insurance at baseline

.307

 Commercial

2,184 (16.9)

1,530 (16.7)

654 (17.2)

 Blue Cross Blue Shield

3248 (25.1)

2,318 (25.3)

930 (24.4)

 Medicaid

477 (3.7)

317 (3.5)

160 (4.2)

 Medicare

6,833 (52.8)

4,831 (52.8)

2,002 (52.6)

 None, self-pay, or unknown

207 (1.6)

146 (1.6)

61 (1.6)